Regensburg, Germany
Geneart AG, founded in 1999, is a leading figure in the burgeoning field of Synthetic Biology. The company leverages its expertise to provide critical technologies essential for the advancement of new therapeutics and vaccines, highlighted by its promise: "GeneArt provide key technologies for the development and production of new therapeutics and vaccines."
The company differentiates itself through a diversified service portfolio encompassing the creation of synthetic genes, gene variants, gene libraries via Directed Evolution, production of plasmid DNA, and the development of mammalian cell lines for protein production. Its operations adhere to the stringent DIN EN ISO 9001:2000 certification, ensuring quality across the service pipeline.
Geneart AG had its last known financial event—a significant acquisition investment—on 01 April 2010. Though specific investor names are not disclosed, this milestone highlights investor confidence in its innovation-driven mission. As the demand for breakthrough biological solutions grows, Geneart AG stands poised for continued impact and evolution.
